{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-006099","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.064861+00:00","generated_at":"2026-06-05T06:28:59.889559+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Puma Biotechnology reports Q4 GAAP net income of $12.3M; guides Q1 2024 net loss of $10-12M","bullets":["Product revenue net Q4 $53.2M (flat YoY); full year $203.1M, up from $200.0M.","GAAP net income Q4 $12.3M ($0.26/diluted) vs net loss $5.6M in Q4 2022.","Non-GAAP adjusted net income Q4 $14.8M ($0.31/share) vs adjusted net loss $3.0M.","Cash and marketable securities $96.0M at Dec 31, 2023, up from $81.1M a year ago.","Guidance: Q1 2024 net product revenue $38-40M, net loss $10-12M; FY2024 net income $12-15M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-006099","json":"https://secwatch.observer/filing/0001437749-24-006099.json","markdown":"https://secwatch.observer/filing/0001437749-24-006099.md","text":"https://secwatch.observer/filing/0001437749-24-006099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774924006099/0001437749-24-006099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774924006099/pbyi20240227_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:28:59.889559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d5170ca017948fa0c7b061d854c629434b7b241","claim":"PUMA BIOTECHNOLOGY, INC. reported financial results for fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On February 29, 2024, Puma Biotechnology, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401667/000143774924006099/0001437749-24-006099-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}